PetVivo Sets Fiscal Fourth Quarter 2025 Conference Call for Monday, June 30 at 5:00 p.m. ET
PetVivo Holdings (OTCQB: PETV), a biomedical company focused on therapeutic medical devices for animals, has scheduled its fiscal fourth quarter and full year 2025 earnings conference call for Monday, June 30, 2025, at 5:00 p.m. ET.
The company will release its financial results for the period ended March 31, 2025, before the conference call. Management will host a presentation followed by a Q&A session. Investors can access the call through a toll-free dial-in number or webcast, with a replay available afterward through the company's investor relations website.
PetVivo Holdings (OTCQB: PETV), un'azienda biomedica specializzata in dispositivi medici terapeutici per animali, ha programmato la conference call per la presentazione dei risultati finanziari del quarto trimestre fiscale e dell'intero anno 2025 per lunedì 30 giugno 2025 alle 17:00 ET.
L'azienda pubblicherà i risultati finanziari relativi al periodo terminato il 31 marzo 2025 prima della conference call. Il management terrà una presentazione seguita da una sessione di domande e risposte. Gli investitori potranno partecipare alla chiamata tramite un numero verde o in webcast, con la possibilità di riascoltare la registrazione successivamente sul sito web delle relazioni con gli investitori dell'azienda.
PetVivo Holdings (OTCQB: PETV), una empresa biomédica centrada en dispositivos médicos terapéuticos para animales, ha programado su llamada de conferencia para los resultados del cuarto trimestre fiscal y del año completo 2025 para el lunes 30 de junio de 2025 a las 5:00 p.m. ET.
La compañía publicará sus resultados financieros correspondientes al período finalizado el 31 de marzo de 2025 antes de la llamada. La dirección realizará una presentación seguida de una sesión de preguntas y respuestas. Los inversores podrán acceder a la llamada a través de un número gratuito o por webcast, con una repetición disponible posteriormente en el sitio web de relaciones con inversores de la empresa.
PetVivo Holdings (OTCQB: PETV)는 동물용 치료 의료기기에 중점을 둔 생명공학 회사로, 2025년 6월 30일 월요일 오후 5시(동부시간)에 2025 회계연도 4분기 및 연간 실적 컨퍼런스 콜을 예정하고 있습니다.
회사는 2025년 3월 31일 종료된 기간의 재무 결과를 컨퍼런스 콜 전에 발표할 예정입니다. 경영진이 프레젠테이션을 진행한 후 질의응답 시간이 이어집니다. 투자자들은 무료 전화번호 또는 웹캐스트를 통해 콜에 참여할 수 있으며, 회사 투자자 관계 웹사이트에서 녹음된 다시 듣기 서비스를 이용할 수 있습니다.
PetVivo Holdings (OTCQB : PETV), une entreprise biomédicale spécialisée dans les dispositifs médicaux thérapeutiques pour animaux, a programmé sa conférence téléphonique sur les résultats du quatrième trimestre fiscal et de l'année complète 2025 pour le lundi 30 juin 2025 à 17h00 ET.
La société publiera ses résultats financiers pour la période close au 31 mars 2025 avant la conférence téléphonique. La direction animera une présentation suivie d'une session de questions-réponses. Les investisseurs pourront accéder à l'appel via un numéro vert ou un webcast, avec une rediffusion disponible ensuite sur le site des relations investisseurs de la société.
PetVivo Holdings (OTCQB: PETV), ein biomedizinisches Unternehmen, das sich auf therapeutische medizinische Geräte für Tiere spezialisiert hat, hat seine Telefonkonferenz für die Ergebnisse des vierten Quartals und des gesamten Geschäftsjahres 2025 für Montag, den 30. Juni 2025, um 17:00 Uhr ET angesetzt.
Das Unternehmen wird die Finanzergebnisse für den zum 31. März 2025 endenden Zeitraum vor der Telefonkonferenz veröffentlichen. Das Management wird eine Präsentation halten, gefolgt von einer Fragerunde. Investoren können über eine gebührenfreie Telefonnummer oder einen Webcast teilnehmen, eine Aufzeichnung wird anschließend auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
MINNEAPOLIS, MN, US, June 26, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Monday, June 30, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal fourth quarter and year ended March 31, 2025. The financial results will be issued in a press release prior to the call.
PetVivo management will host the presentation, followed by a question-and-answer period.
Date: Monday, June 30, 2025
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: +1 253 205 0468
Conference ID: 83424004566
Passcode: 352845
Webcast (live and replay): click here
A replay of the webcast will be available through the same link following the conference call.
The conference call webcast replay will also be available via a link in the Investors section of the company’s website at petvivo.com/investors.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
When is PetVivo's (PETV) Q4 2025 earnings call?
How can investors access PetVivo's (PETV) Q4 2025 earnings call?
Where can I find the replay of PetVivo's (PETV) Q4 2025 earnings call?
What period will PetVivo's (PETV) earnings report cover?
